We are live on ! Find out more
EWTX icon

Edgewise Therapeutics

46 hedge funds and large institutions have $1.03B invested in Edgewise Therapeutics in 2021 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

188% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 8

50% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 6

48% more funds holding

Funds holding: 3146 (+15)

1.18% more ownership

Funds ownership: 96.03%97.21% (+1.2%)

20% less funds holding in top 10

Funds holding in top 10: 54 (-1)

30% less capital invested

Capital invested by funds: $1.48B → $1.03B (-$449M)

Holders
46
Holders Change
+15
Holders Change %
+48.39%
% of All Funds
0.8%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.07%
New
23
Increased
9
Reduced
6
Closed
8
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
CCM
51
CAAS Capital Management
New York
-$975K -30,000 Closed
Squarepoint
52
Squarepoint
New York
-$656K -20,185 Closed
LCM
53
Landscape Capital Management
New Jersey
-$290K -8,923 Closed
MS
54
Maven Securities
Jersey
-$262K -8,300 Closed

EWTX Hedge Fund Activity: Q2 2021 in Review

46 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q2 2021, worth a combined $1.03B — down 30% from $1.48B a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new EWTX positions and 8 closed out — a net gain of 15 holders — while 9 added to existing stakes and 6 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $24.2M. The largest seller was Viking Global Investors, cutting an estimated $17.1M.

  • 46 institutional investors held Edgewise Therapeutics (EWTX) as of Q2 2021, up from 31 in Q1 2021.
  • Funds reported $1.03B of Edgewise Therapeutics stock for Q2 2021, down 30% quarter-over-quarter.
  • 23 funds opened new Edgewise Therapeutics positions in Q2 2021 and 8 closed out, a net change of +15 holders.
  • The largest Edgewise Therapeutics buyer in Q2 2021 was Fidelity Investments, an estimated $24.2M added.
  • The largest Edgewise Therapeutics seller in Q2 2021 was Viking Global Investors, an estimated $17.1M sold.

Based on aggregated 13F filings for Q2 2021.